Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: November 3, 2021
Reporting Period: Quarter ended September 30, 2021
Business Context: The filing serves as a notification that the Company issued a press release announcing its financial results for the third quarter of 2021 and providing a business update. The Company is an emerging growth company incorporated in Nevada.
Key Financial Metrics
The provided Form 8-K text acts as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text itself does not provide specific values for the following metrics:
- Revenue: Not stated in this document.
- Profit/Loss: Not stated in this document.
- Cash Flow: Not stated in this document.
- Margins: Not stated in this document.
- Debt and Liquidity: Not stated in this document.
Material Changes
The filing text does not contain specific comparative data or descriptions of material changes versus the prior comparable period. It only indicates that such information is contained within the attached press release.
Guidance, Outlook, and Risks
Management Commentary: The Company announced a business update alongside financial results, though specific commentary is not included in the 8-K text.
Forward-Looking Statements: The filing includes a standard disclaimer stating that the information furnished in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other registration statements unless expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached Press Release) to obtain actual revenue, net loss, cash position, and operating expense figures for the quarter ended September 30, 2021.
- Verify the specific details of the "business update" mentioned in the press release, as the 8-K does not summarize operational milestones.
- Confirm the Company's status as an "emerging growth company" and any implications for financial reporting standards.
- Check subsequent filings for any updates to the liquidity position or capital raise activities referenced in the Q3 results.